PCVX
MaterialsVaxcyte Inc
$57.10+1.46 (+2.62%)PRE
Live · NASDAQ · May 9, Close
AI Insight
What's Moving PCVX Today?
No stock-specific AI insight has been generated for PCVX yet. Check back soon — insights are generated from recent news analysis.
Fundamentals
Market Cap$8.2B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding144.4M
PCVX News
20 articles- Vaxcyte Reports First Quarter 2026 Financial Results and Provides Business UpdateYahoo Finance·May 6, 2026
- Vaxcyte Inc (PCVX)’s VAX-31 Enters Critical Trial StageYahoo Finance·Apr 23, 2026
- Is It Too Late To Consider Vaxcyte (PCVX) After A 95% One-Year Share Price Jump?Yahoo Finance·Apr 11, 2026
- Vaxcyte to Present at the 25th Annual Needham Virtual Healthcare ConferenceYahoo Finance·Apr 7, 2026
- Vaxcyte Completes Enrollment of OPUS-1 and OPUS-2 Phase 3 Trials Evaluating VAX-31 for the Prevention of Invasive Pneumococcal Disease and Pneumonia in AdultsYahoo Finance·Mar 23, 2026
- High-Flying Biotech Stock Up 360% Faces $48 Million Trim but Remains This Fund's Largest HoldingMotley Fool·Mar 21, 2026
- Positive VAX-31 Phase 1/2 Adult Data Published in The Lancet Infectious Diseases Highlight Best-in-Class Potential of Vaxcyte’s 31-Valent Pneumococcal Conjugate Vaccine (PCV) CandidateYahoo Finance·Mar 18, 2026
- Does Heavy 2025 Loss and Large Equity Raise for Vaxcyte’s VAX-31 Shift the Bull Case (PCVX)?Yahoo Finance·Mar 2, 2026
- Love A Little Risk? Wall Street Sees Massive Upside in Vaxcyte Stock.Barchart·Mar 2, 2026
- Vaxcyte Advances VAX-31 Toward Phase 3 As Valuation Gap PersistsYahoo Finance·Mar 2, 2026
- A Look At Vaxcyte (PCVX) Valuation As Share Price Momentum RebuildsYahoo Finance·Mar 2, 2026
- Vaxcyte, Inc. Q4 2025 Earnings Call SummaryMoby·Feb 25, 2026
- Vaxcyte Q4 Earnings Call HighlightsMarketbeat·Feb 25, 2026
- Vaxcyte Inc (PCVX) Q4 2025 Earnings Call Highlights: Unprecedented Phase 2 Results and ...Yahoo Finance·Feb 25, 2026
- Vaxcyte Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Feb 24, 2026
- Vaxcyte Inc. (PCVX) Confident of Topline Data in Pneumococcal Vaccine TrialsYahoo Finance·Feb 19, 2026
- Vaxcyte (PCVX) $632.5M Stock Offering Follows Bullish Cantor Fitzgerald RatingYahoo Finance·Feb 19, 2026
- Impressive Clinical Pipeline Leads to Bullish Sentiment for Vaxcyte (PCVX)Yahoo Finance·Feb 16, 2026
- Should Vaxcyte’s OPUS-3 Phase 3 VAX-31 Trial Milestone Require Action From Vaxcyte (PCVX) Investors?Yahoo Finance·Feb 15, 2026
- Vaxcyte Spotlights VAX-31 Phase 3 Launch, Eyes Adult BLA by End of Next Year at Biotech SummitMarketbeat·Feb 14, 2026
All 20 articles loaded
Price Data
Open$56.00
Previous Close$55.64
Day High$57.33
Day Low$55.08
52 Week High—
52 Week Low—
Fundamentals
Market Cap$8.2B
P/E Ratio—
EPS—
Dividend Yield—
Dividend / Share—
ROE—
Profit Margin—
Debt / Equity—
Trading
Volume1.6M
Avg Volume (10D)—
Shares Outstanding144.4M
About Vaxcyte Inc
Vaxcyte Inc is a clinical-stage vaccine company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It uses the XpressCF cell-free protein synthesis platform to develop potentially superior and novel conjugate and protein vaccine candidates for adult and pediatric indications. The company's product pipeline includes: VAX-31, VAX-24, and VAX-XL PCV vaccine candidates; VAX-A1, a Novel Group A Strep Vaccine; and VAX-GI, a Novel Shigella Vaccine, among others, in their different stages of development.
MaterialsBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Company Details
Security TypeStock
ExchangeNASDAQ
Currency—
Round Lot—
SICBIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
CIK—
Composite FIGI—
Share Class FIGI—